BRKR Stock - Bruker Corporation
Unlock GoAI Insights for BRKR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.37B | $2.96B | $2.53B | $2.42B | $1.99B |
| Gross Profit | $1.65B | $1.51B | $1.31B | $1.21B | $939.80M |
| Gross Margin | 49.0% | 51.0% | 51.6% | 50.0% | 47.3% |
| Operating Income | $253.10M | $436.90M | $432.70M | $413.30M | $248.30M |
| Net Income | $113.10M | $427.20M | $296.60M | $277.10M | $157.80M |
| Net Margin | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% |
| EPS | $0.76 | $2.92 | $2.00 | $1.83 | $1.03 |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | Wolfe Research | Upgrade | Outperform | $60 |
| December 9th 2025 | Goldman | Initiation | Sell | $40 |
| November 20th 2025 | Rothschild & Co Redburn | Initiation | Buy | $60 |
| May 22nd 2025 | Citigroup | Downgrade | Neutral | $40 |
| December 19th 2024 | Guggenheim | Initiation | Buy | $72 |
| December 10th 2024 | UBS | Initiation | Neutral | $66 |
| December 5th 2024 | Goldman | Upgrade | Neutral | $60 |
| October 15th 2024 | Barclays | Initiation | Overweight | $75 |
| September 30th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| August 28th 2024 | Wells Fargo | Initiation | Overweight | $78 |
| June 3rd 2024 | Jefferies | Resumed | Buy | $85 |
| February 14th 2024 | JP Morgan | Upgrade | Overweight | $90← $60 |
| December 19th 2023 | Wells Fargo | Initiation | Equal Weight | $72 |
| December 13th 2023 | Wolfe Research | Initiation | Outperform | $80 |
| October 21st 2022 | UBS | Initiation | Buy | $70 |
Earnings History & Surprises
BRKREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $0.65 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.33 | $0.60 | +81.8% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $0.33 | $0.32 | -3.0% | ✗ MISS |
Q2 2025 | May 7, 2025 | $0.46 | $0.47 | +2.2% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $0.75 | $0.76 | +1.3% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $0.61 | $0.60 | -1.6% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $0.52 | $0.52 | 0.0% | = MET |
Q2 2024 | May 2, 2024 | $0.46 | $0.53 | +15.2% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $0.65 | $0.70 | +7.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.63 | $0.74 | +17.5% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.49 | $0.50 | +2.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.55 | $0.64 | +16.4% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $0.72 | $0.74 | +2.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.55 | $0.66 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.45 | $0.45 | 0.0% | = MET |
Q2 2022 | May 4, 2022 | $0.42 | $0.49 | +16.7% | ✓ BEAT |
Q1 2022 | Feb 11, 2022 | $0.58 | $0.59 | +1.7% | ✓ BEAT |
Q4 2021 | Nov 1, 2021 | $0.44 | $0.63 | +43.2% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | $0.38 | $0.44 | +15.8% | ✓ BEAT |
Latest News
Bruker Reports Preliminary Q4 2025 Revenue Of $965M-$970M; Expects 2026 Organic Revenue Growth Flat To Low-Single-Digit, Sees Double-Digit Non-GAAP EPS Growth
➖ NeutralBruker Announces Two Multi-Year Superconductor Supply Agreements Worth About $500M In Expected Future MRI Revenues, Including One Extending Up To Seven Years
📈 PositiveBruker Acquires Remaining Stake In TOFWERK, Expanding Ultra-Fast TOF Mass Spectrometry Portfolio Into Applied Small Molecule Markets; Terms Not Disclosed
📈 PositiveTD Cowen Maintains Hold on Bruker, Raises Price Target to $53
➖ NeutralGuggenheim Maintains Buy on Bruker, Raises Price Target to $53
📈 PositiveBruker's RI Research Instruments Secures Over $40M In ELI-NP Contracts, Deliveries Slated For Late 2026
📈 PositiveAbCellera settles patent litigation with Bruker over microfluidic device tech
📈 PositiveAbCellera Strikes Patent License Deal With Bruker; Bruker To Pay $36M As Future Royalty Payments On Sales Of Beacon Optofluidic Platform Globally
📈 PositiveBarclays Maintains Overweight on Bruker, Raises Price Target to $55
📈 PositiveJP Morgan Maintains Overweight on Bruker, Raises Price Target to $55
📈 PositiveWells Fargo Maintains Overweight on Bruker, Raises Price Target to $55
📈 PositiveB of A Securities Maintains Buy on Bruker, Raises Price Target to $60
📈 PositiveWolfe Research Upgrades Bruker to Outperform, Announces $60 Price Target
📈 PositiveBruker Secures $25M In European Orders For High-Performance NMR And EPR Systems From ENS-PSL, MPI-FKF And IECB With Revenue In 2026–2027 And Second 1.2 GHz NMR Accepted At University Of Birmingham
📈 PositiveGoldman Sachs Initiates Coverage On Bruker with Sell Rating, Announces Price Target of $40
📉 NegativeIndaba Capital Management Announces It Has Sold Its Portfolio Company, AST Revolution To Bruker Corporation; Financial Details Not Disclosed
➖ NeutralRothschild & Co Initiates Coverage On Bruker with Buy Rating, Announces Price Target of $60
📈 PositiveWells Fargo Maintains Overweight on Bruker, Lowers Price Target to $48
➖ NeutralTD Cowen Maintains Hold on Bruker, Raises Price Target to $42
➖ NeutralUBS Maintains Neutral on Bruker, Raises Price Target to $43
➖ NeutralFrequently Asked Questions about BRKR
What is BRKR's current stock price?
What is the analyst price target for BRKR?
What sector is Bruker Corporation in?
What is BRKR's market cap?
Does BRKR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BRKR for comparison